New drug cocktail aims to stop lung cancer return in Early-Stage patients
NCT ID NCT07485920
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs, tislelizumab and nintedanib, can help control limited-stage small cell lung cancer after standard chemoradiation. About 20 adults with good performance status will receive this consolidation therapy. The goal is to delay cancer progression and improve survival, while monitoring side effects like lung inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
-
Qingdao Central Hospital Affiliated to Rehabilitation University
Qingdao, Shandong, China
-
Qingdao Municipal Hospital
Qingdao, Shandong, China
-
Weihai Municipal Hospital
Weihai, Shandong, China
-
Yantai Yuhuangding Hospital
Yantai, Shandong, China
-
Zibo Fourth People's Hospital
Zibo, Shandong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.